Maxim Group Maintains a 'Buy' Rating on Given Imaging (GIVN); Raises PT
More News related to GIVN
- Given Imaging (GIVN) Announces the Degree of Impact the PillCam SB has on GI Patients, Crohn's Disease
- Three Studies Find PillCam(R) SB Enables Earlier Diagnosis and Treatment of GI Diseases Including Crohn's
- Given Imaging (GIVN) Announces Viability of PillCam Capsule in Pediatric Patients
- Given Imaging Announces RAPID(R) pH Software for Bravo(R) pH Monitoring System
- New Studies Show PillCam(R) SB to Be Clinically Valuable in Classifying and Managing Pediatric GI Symptoms
More News related to Analyst Comments
- Green Mountain (GMCR) Will Likely Win Diedrich Coffee (DDRX) Bidding War - Analyst
- FBR Capital Raises Estimates & PT on Trina Solar (TSL) following 3Q09 results
- Broadpoint.AmTech Reiterates a 'Buy' on Precision Castparts (PCP); Issues Top Ten for Owning Shares
- Citi Recommends Stocks in Qatar, UAE, Egypt; Believes Middle East Will 'Catch Up' to Emerging Markets
- Broadpoint.AmTech Maintains a 'Buy' on First Solar (FSLR); Lowers PT and Estimates
Maxim Group maintains a 'Buy' rating on Given Imaging (Nasdaq: GIVN), raises price target from $15 to $21.
To see more analyst ratings on GIVN Click Here.
Given Imaging Ltd. develops, manufactures, and markets diagnostic products for the visualization and detection of disorders of the gastrointestinal tract.
Related Categories
Analyst CommentsStocks Mentioned
+0.21Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
